	Isaksson 2006	Bacman 2007	Li 2011	Isaksson 2012	Lampropoulos 2012	Roth 2012	Voorneveld 2013	Alazzouzi 2005	Alhopuro 2005	Baraniskin 201 Mesker 2009 Gulubova 2010		Ahn 20	109	
study group														
population described														
Gender/age		1	1	1	1	1	1	1	1	1	1 1		I	1
Histology		1	1	1	1	1	1	1	1	1	1 1		I	1
period of recruitment		1	1	1	1		0	1	1	1	0 1		I	1
Inclusion/exclusion		1	1	0	1	1	0	1	1	1	1 1		1	1
Study attrition														
>90% of identified included in final analysis		0	1	1	1	1	1	1	1	1	0 1		J	1
Reasons for loss to follow up given		1	1	0	1	1	1	1	1	1	1 1	(0	0
Peri-operative mortality details		1	1	0	0	1	0	0	0	0	1 1		0	0
Scientific methodology														
IHC methodology outlined														
Details of 1ste/2nd Abs used		1	1	1	1	1	1	1	1	1	1 1		1	1
Concentration		1	1	1	1	1	1	1	1	1	1 1		1	1
Positive negative control		1	1	0	1	1	0	1	0	0	0 1		1	1
Description scoring system														
>1 independent scorer		1	0	1	1	1	1	1	1	1	1 0		I	1
Blind		0	0	1	1	1	1	1	1	1	1 0	(0	0
Criteria for positive outlined														
Distribution (membr vs nuclear)			0	1	1		0			0	1 1		I	0
% pos for classification stated		1	0	0	1	1	0	1	0	0	1 1		1	1
Confounding factors considered														
Adjuvant therapy details provided		1	1	0	0	1	1	1	1	1	1 1		1	1
Histology breakdown according to IHC staining		1	1	1	1	1	1	1	1	1	0 0	•)	1
Statistical analysis														
HR (CI) provided		1	1	1	1	1	1	1	0	0	0 0	(J	0
Exact p-value		1	1	1	1	1	1	1	1	1	1 1		1	1
number at risk for Kaplan Meier		1	1	1	1	0	1	1	1		1 1		1	1
Number of censored cases		1	0	0	0	0	1	1	1	1	0 0	()	1
<u>total</u>		17 1	5	13	17	17 1	4 1	9 1	5 1	5 1	4 15	1;	3	15